Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
ProCE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Clinical Pharmacy Specialist
Hematology/Oncology, Stem Cell Transplant, and Cellular Therapy
Department of Pharmacy
Hospital of the University of Pennsylvania
Clinical Pharmacy Specialist
Adult Bone Marrow Transplant Service
Memorial Sloan Kettering Cancer Center
New York, New York
Vice President, Scientific Services
Senior Clinical Editor
Senior Director, Educational Strategy
Director, CME Program Development
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
The target audience for this activity is pharmacists, including clinical, managed care, and specialty pharmacists, who care for patients with hematologic malignancies that are eligible for CAR T-cell therapy as well other stakeholders in hematology/oncology practice.
ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-090-H01-P has been assigned to this home study, application-based activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 65% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 28, 2022, through April 27, 2023:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Pharmacists review the latest findings in the treatment of relapsed/refractory multiple myeloma and provide clinical insights based on their personal experiences, from Clinical Care Options (CCO).
Downloadable slideset on advances in relapsed/refractory multiple myeloma, from ProCE, LLC in partnership with Clinical Care Options (CCO).
On-demand webcast from ProCE and Clinical Care Options (CCO), Rebecca Gonzalez, PharmD, BCOP, and Bhavesh Shah, RPh, BCOP, discuss the management of relapsed/refractory multiple myeloma
Rebecca Gonzalez, PharmD, BCOP, discusses key pharmacy strategies for management of patients with multiple myeloma in this commentary from Clinical Care Options (CCO)